Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906902 | 0.89 | LMNA (0.43) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8905658 | 0.88 | LMNA (0.42) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL12845800 | 0.81 | LMNA (0.58) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8763555 | 0.80 | LMNA (0.42) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL13797744 | 0.79 | LMNA (0.55) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8379840 | 0.78 | LMNA (0.39) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL24217642 | 0.78 | LMNA (0.41) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL1359798 | 0.78 | LMNA (0.38) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8905420 | 0.78 | LMNA (0.54) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8905637 | 0.78 | LMNA (0.54) | LMNACYP2C19HIF1AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | disclosed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | disclosed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| EP-2245004-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885CYP2C19 3568/4885HIF1A 337/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885CYP2C19 3568/4885HIF1A 337/4885 |
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | LMNA 1002/4885CYP2C19 2085/4885HIF1A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.